Octosense for Bladder Cancer

About Cellens

Founded in 2018 and based in Cambridge, Massachusetts, Cellens is developing the Octosense platform, a diagnostic technology that uses atomic force microscopy (AFM) to scan cell surfaces at the nanoscale and machine learning to analyze the biophysical data. The company's lead application is a non-invasive urine test for monitoring bladder cancer recurrence, with preliminary clinical data showing 94% accuracy. Backed by a $6.5M funding round and strategic partnerships, Cellens is positioning itself at the intersection of mechanobiology and AI to create a new class of cancer diagnostics.

Therapeutic Areas